FIELD: pharmaceutics.
SUBSTANCE: group of inventions relates to pharmaceutics. 3 versions of modified release pharmaceutical compounds containing immediate release beads of febuxostat are described, as well as the beads of febuxostat of extended or delayed/controlled, or controlled release formulations in different ratios. 2 versions of graduated dose containing said pharmaceutical compounds and a method of treating a patient suffering from gout or hyperuricemia are also described.
EFFECT: group of inventions provides high levels of xanthine oxidase inhibition when the concentration of active substance is greater than about 0,1
μg/mL for a period of from about 5 hours to about 24 hours.
24 cl, 12 dwg, 17 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HELICOBACTER PYLORI | 2014 |
|
RU2671400C2 |
| TREATMENT OF ESSENTIAL TREMOR, USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUORETHOXY)PYRIDINE-2-YL)ETHYL)ACETAMIDE | 2019 |
|
RU2780318C1 |
| COMPOSITIONS OF L-ORNITHINE PHENYL ACETATE | 2016 |
|
RU2755904C2 |
| TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS | 2014 |
|
RU2674345C2 |
| EXTENDED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF | 2013 |
|
RU2599017C2 |
| ORAL DOSAGE FORMS OF TOFACITINIB WITH CONTINUOUS RELEASE | 2014 |
|
RU2790166C2 |
| DOSAGE FORMS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND THEIR APPLICATION | 2011 |
|
RU2609833C2 |
| PHARMACEUTICAL COMPOSITIONS WITH DEFERRED RELEASE CONTAINING VALPROIC ACID AND THEIR USE | 2017 |
|
RU2760304C2 |
| COMPOSITIONS AND METHODS FOR TREATING VISUAL ORGAN DISORDERS | 2018 |
|
RU2761436C1 |
| USE OF COMPOSITION FOR NON-HORMONAL CONTRACEPTION AND PACKAGING | 2019 |
|
RU2799756C2 |
